Jill F. Wright

TL;DR: These experiments of nature indicate that human IL-17A andIL-17F are essential for mucocutaneous immunity against C. albicans, but otherwise largely redundant.

TL;DR: It is shown for the first time that myostatin acts postnatally as a negative regulator of skeletal muscle growth and suggest that hisostatin inhibitors could provide a therapeutic benefit in diseases for which muscle mass is limiting.

TL;DR: A potent myostatin inhibitor, a soluble form of the activin type IIB receptor (ACVR2B), is described, which can cause dramatic increases in muscle mass when injected into wild-type mice.

TL;DR: Findings raise the possibility that members of the BMP-1/TLD family may be involved in activating latent myostatin in vivo and that molecules capable of inhibiting these proteinases may be effective agents for increasing muscle mass for both human therapeutic and agricultural applications.

TL;DR: The data elucidate the regulation of IL-17F/A heterodimer expression by Th17 cells and demonstrate an in vivo function for this cytokine in airway neutrophilia.